Grifols (GRFS) Change in Working Capital (2010 - 2016)
Grifols' (GRFS) quarterly Change in Working Capital came in at $25.1 million in Q4 2016, up 118.4% YoY from $11.5 million in Q1 2016, and down 41.73% on a QoQ basis from $43.0 million in Q3 2016.
Grifols (GRFS) Change in Working Capital (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Change in Working Capital data on file, last reported at $25.1 million in Q4 2016.
- Quarterly Change in Working Capital rose 118.4% year-over-year to $25.1 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $19.1 million (down 76.91% YoY) and the FY2025 annual result came in at $36.1 million, up 246.82% from the prior year.
- Change in Working Capital retreated to $25.1 million in Q4 2016, from $43.0 million in the prior quarter.
- In the past five years, Change in Working Capital ranged from a high of $327.9 million in Q3 2014 to a low of -$308.5 million in Q4 2014.
- A 5-year average of $45.0 million and a median of $69.0 million in 2013 frame the typical range for Change in Working Capital.
- Annual changes were most pronounced in 2013 — Change in Working Capital soared 109931.64% — and 2014, when it plunged 594.81%.
- Tracing GRFS's Change in Working Capital over 5 years: stood at $109.7 million in 2012, then tumbled by 43.15% to $62.4 million in 2013, then tumbled by 594.81% to -$308.5 million in 2014, then soared by 55.82% to -$136.3 million in 2015, then surged by 118.4% to $25.1 million in 2016.
- The last three Change in Working Capital figures came in at $25.1 million (Q4 2016), $43.0 million (Q3 2016), and -$136.3 million (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 25.08 Mn |
| Dec 31, 2016 | 25.08 Mn |
| Sep 30, 2016 | 43.04 Mn |
| Sep 30, 2016 | 43.04 Mn |
| Dec 31, 2015 | -136.30 Mn |
| Dec 31, 2015 | -136.30 Mn |
| Sep 30, 2015 | 87.24 Mn |
| Sep 30, 2015 | 87.24 Mn |
| Jun 30, 2015 | 326.79 Mn |
| Jun 30, 2015 | 326.79 Mn |
| Mar 31, 2015 | -195.16 Mn |
| Mar 31, 2015 | -195.16 Mn |
| Dec 31, 2014 | -308.52 Mn |
| Dec 31, 2014 | -308.52 Mn |
| Sep 30, 2014 | 327.88 Mn |
| Sep 30, 2014 | 327.88 Mn |
| Jun 30, 2014 | -120.20 Mn |
| Jun 30, 2014 | -120.20 Mn |
| Mar 31, 2014 | 120.25 Mn |
| Mar 31, 2014 | 120.25 Mn |